SYLVIA AND CHARLES VIERTEL CHARITABLE FOUNDATION MARKS 30 YEARS MILESTONE IN FUNDING RESEARCH New Fellowships to researchers in cancer metastasis, epigenomics and AI in early disease diagnosis & management
With
Associate Professor Paul Ekert, Co-Chair,
Medical Advisory Board, Sylvia and Charles Viertel Charitable Foundation
SEGMENT
Filmed in Sydney, Melbourne & Adelaide | December 2025
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
In late October 2025, the Sylvia and Charles Viertel Charitable Foundation, in association with Bellberry, announced the recipients of the 2025 Viertel Senior Medical Research Fellowships. Three Australian mid-career researchers who are advancing solutions for major illnesses including cancer, cardiovascular disease, and neurodegenerative diseases. The 2025 Viertel Senior Medical Research Fellows, who will each receive $1.375 million over five years to support their work, are:
- Dr Joanna Achinger-Kawecka, SAiGENCI for her work in advancing cancer therapy utilising innovative 3D chromatin structure mapping technology.
- Dr Dustin Flanagan, Monash Biomedicine Discovery Institute, Monash University, for addressing the impact of direct cell damage on gastric cancer initiation and progression.
- Associate Professor Zongyuan Ge, Monash AIM for Health Lab, Monash University for developing a personalised healthcare model integrating diverse patient information collected over time via AI. He is the recipient of a Bellberry-Viertel Senior Medical Research Fellowship.
The Viertel Foundation over 30 years has had significant impact in medical research, including
- Awarding 70 fellowships since 1995, each currently providing $1.375 million over five years to support Australia’s top mid-career researchers.
- 162 Clinical Investigator Awards providing $90,000 over one year have been granted, supporting early-career clinicians and stimulating clinical research across Australia.
- Research infrastructure grants totalling $2.45 million have been awarded, recognising the importance of establishing and maintaining the facilities required for world-class research environments.
- The combined total value of the Clinical Investigator Awards, the Fellowships, and infrastructure grants – including the most recent awards has reached $90,001,250. This substantial investment underscores the Foundation’s enduring commitment to advancing medical research and improving health outcomes for Australians.
- Funding has enabled breakthroughs in cancer, infectious diseases, respiratory illnesses, dementia, stem cell research, and more – directly impacting millions of Australians each year.
Source: Adapted from Equity Trustees media release
Photo Credit: Charles Viertel Photo, Queensland Eye Institute
Photo Credit: AAHMS Gala Dinner, Canberra November 2025, Australian Academy of Health and Medical Sciences
-
Empowered nurses leading digital health enablement
Nurses have a pivotal role to play in the widespread implementation and adoption of digital health technologies throughout the healthcare sector for the primary purpose of improving safety and quality of patient care.
Australian Health Journal talked to two of Australian top leaders in nursing and in digital health on how the role of nursing is pivotal to the success of digital health in the Australian health system.
-
Addressing Wound Management
The cost of chronic wounds in Australia is estimated to be $3 Billion per year, impacting 420,000 Australians. Not only is this a national economic concern, but more importantly, is the suffering the person may be going through.
Australian Health Journal met with Hayley Ryan, Board Director and Chair at Wounds Australia and Director at WoundRescue to hear her work in chronic wound management, palliative wounds and pressure injury prevention to comfort those living with a wound.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
